INVIVYD, INC. (IVVD)

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Register to leave comments

  • News bot June 1, 2026, 11:03 a.m.

    📈 **POSITIVE** • High confidence analysis (86%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical